Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 known ✓ | P31644 | 4/20 | 0.43 |
| ▸ | GABRB2 known ✓ | P47870 | 3/20 | 0.43 |
| ▸ | GABRA1 known ✓ | P14867 | 3/20 | 0.43 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.43 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.43 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.43 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.43 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.43 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.43 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.43 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.43 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.43 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.43 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.43 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.43 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.37 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8873859 | 0.98 | GABRA5 (0.44) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL16849096 | 0.85 | SLC6A1 (0.39) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL29508661 | 0.85 | SLC6A1 (0.39) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL9827947 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL6491730 | 0.81 | GABRA5 (0.37) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL12928717 | 0.80 | GABRA5 (0.39) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL15910211 | 0.80 | GABRA5 (0.44) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL2398071 | 0.78 | GABRA5 (0.38) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL28196953 | 0.78 | GABRA5 (0.43) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| Hydrochloric Acid SCHEMBL1049098 | 0.78 | EPHX1 (0.36) | GABRA5GABRB2GABRA1GABRA4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | NOVOSTAR PHARMACEUTICALS, LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4338737-A1 | PARP7 INHIBITOR AND USE THEREOF | Novostar Pharmaceuticals, Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| CN-110392678-B | Compounds and methods for IDO and TDO modulation, and indications therefor | 普莱希科公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3921313-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | PLEXXIKON INC. (US) | 2021-10-19 | — | — | US | disclosed |
| CN-112119072-A | Compounds and methods for IDO and TDO modulation, and indications thereof | 普莱希科公司 | 2020-12-22 | — | — | CN | disclosed |
| WO-2020161623-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-08-13 | — | — | WO | disclosed |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-10-03 | — | — | US | disclosed |
| EP-3515892-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2004080952-A1 | PHENYLSULFONAMIDE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE | BAYER HEALTHCARE AG (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149011-B2 | Compounds and methods for IDO and TDO modulation, and indications therefor | IDO1, TDO2, IDO2 | GABRA5 1574/4885GABRB2 1629/4885GABRA1 1368/4885 |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | PARP1, PARP3, PARP11 | GABRA5 3390/4885GABRB2 4035/4885GABRA1 3518/4885 |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | GABRA5 1643/4885GABRB2 1521/4885GABRA1 1153/4885 |
| US-20190300487-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | GABRA5 1574/4885GABRB2 1629/4885GABRA1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.